Health Canada has approved the first generic versions of Novo Nordisk's diabetes drug Ozempic, made by Dr. Reddy's Laboratories and Apotex, marking the first generics available in North America. These generics are currently only available in Canada, with seven more under review, and may lead to price reductions and revenue declines for Novo Nordisk internationally. The company expects a low single-digit impact and is using savings cards to retain customers. A significant price cut of 65% will be mandated once three generics enter the Canadian market, which Novo Nordisk is prepared to handle strategically. This development will serve as a test for generic competition against branded GLP-1 drugs.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce sid...
